# Sungwon Lim

> Dr. Sungwon Lim is the CEO and Co-Founder of ImpriMed, Inc., a Palo Alto-based precision oncology company that combines live cancer cell testing with AI to predict which drugs will work best for an individual patient's cancer - before treatment begins. Having raised $23M in Series A funding led by SoftBank Ventures Asia, ImpriMed has helped treat over 6,500 dogs with blood cancers across 130+ specialty hospitals in the US, Canada, England, and France, while publishing clinical data showing AI predictions tripled survival rates in relapsed B-cell lymphoma. A Stanford-trained bioengineer inspired by the potential of one powerful medicine to save millions, Lim pioneered a pivot into veterinary oncology as a proving ground before expanding the platform to human cancer treatment.

- **Role:** CEO, Co-Founder at ImpriMed, Inc.
- **Organizations:** ImpriMed, Inc., Stanford University (alumni), UC Berkeley-UCSF Joint Bioengineering Program (alumni)
- **Nationality:** Korean-American
- **Education:** PhD in Bioengineering, Stanford University, Master's degree in Translational Medicine, UC Berkeley - UCSF Joint Bioengineering Program
- **Known for:** Raised over $63.85M in total funding including $23M Series A led by SoftBank Ventures Asia, Built ImpriMed to serve 200+ veterinary oncologists across 130+ specialty hospitals in the US, Canada, England, and France, AI predictions shown to triple survival rates and quadruple response rates in relapsed canine B-cell lymphoma

## Career timeline

- **2017** — Completed PhD in Bioengineering at Stanford University
- **2017** — Co-founded ImpriMed, Inc. in Palo Alto, CA with Jamin Koo
- **2018** — ImpriMed closed Seed funding round
- **2021** — ImpriMed commercialized first services; raised $8M Pre-Series A
- **2021** — Featured in Authority Magazine 'Meet The Inventors' series
- **2022** — Named 'Top Industry Leader' by Life Sciences Voice
- **2022** — Named to '40 Under 40 in Cancer' Class of 2022
- **2022** — ImpriMed serving 250+ veterinary oncologists across 40+ US states
- **2023** — Raised $23M Series A led by SoftBank Ventures Asia with SK Telecom as strategic investor
- **2024** — ImpriMed has treated 6,500+ dogs, serving 200+ veterinary oncologists at 130+ specialty hospitals

## Achievements

- Raised over $63.85M in total funding including $23M Series A led by SoftBank Ventures Asia
- Built ImpriMed to serve 200+ veterinary oncologists across 130+ specialty hospitals in the US, Canada, England, and France
- AI predictions shown to triple survival rates and quadruple response rates in relapsed canine B-cell lymphoma
- Named to '40 Under 40 in Cancer' Class of 2022
- Named 'Top Industry Leader' by Life Sciences Voice in 2022
- Published clinical research in Frontiers in Oncology, npj Precision Oncology, and other peer-reviewed journals
- Secured strategic partnership with SK Telecom for AI development
- 6,500+ dogs treated through ImpriMed's precision oncology platform
- 95% oncologist satisfaction rate across 87 surveyed veterinary oncologists

## Latest updates

- **2023-12** — ImpriMed raised $23M Series A led by SoftBank Ventures Asia; SK Telecom joined as strategic partner
- **2024** — ImpriMed surpassed 6,500 dogs treated through its AI-powered precision oncology platform across 130+ specialty hospitals
- **2023-12** — TechCrunch covered ImpriMed's ambitions to expand AI technology from veterinary to human oncology

## Links

- Website: https://imprimedicine.com
- LinkedIn: https://www.linkedin.com/in/sungwon-lim
- Twitter/X: https://twitter.com/imprimedicine
- Facebook: https://www.facebook.com/imprimedicine

---

Profile page: https://yespress.io/sungwon-lim
Published by YesPress — https://yespress.io
Last updated: 2026-05-14